Display options
Cite
O'Riordan E, Orlova TN, Mendelev N, et al. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2008;2(7):1025-35doi: 10.1002/prca.200780137.
O'Riordan, E., Orlova, T. N., Mendelev, N., Patschan, D., Kemp, R., Chander, P. N., Hu, R., Hao, G., Gross, S. S., Iozzo, R. V., Delaney, V., & Goligorsky, M. S. (2008). Urinary proteomic analysis of chronic allograft nephropathy. Proteomics. Clinical applications, 2(7), 1025-35. https://doi.org/10.1002/prca.200780137
O'Riordan, Edmond, et al. "Urinary proteomic analysis of chronic allograft nephropathy." Proteomics. Clinical applications vol. 2,7 (2008): 1025-35. doi: https://doi.org/10.1002/prca.200780137
O'Riordan E, Orlova TN, Mendelev N, Patschan D, Kemp R, Chander PN, Hu R, Hao G, Gross SS, Iozzo RV, Delaney V, Goligorsky MS. Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin Appl. 2008 Jul;2(7):1025-35. doi: 10.1002/prca.200780137. PMID: 21136903; PMCID: PMC4690473.
Copy Download .nbib Format: NLM
Share it on

Proteomics Clin Appl. 2008 Jul;2(7):1025-35. doi: 10.1002/prca.200780137.

Urinary proteomic analysis of chronic allograft nephropathy.

Proteomics. Clinical applications

Edmond O'Riordan, Tatyana N Orlova, Natalia Mendelev, Daniel Patschan, Rowena Kemp, Praveen N Chander, Rena Hu, Gang Hao, Steven S Gross, Renato V Iozzo, Veronica Delaney, Michael S Goligorsky

Affiliations

  1. Department of Renal Medicine, Salford Royal Foundation Trust, Salford, UK; Department of Medicine, Renal Institute and Division of Nephrology, New York Medical College, Valhalla, NY, USA. edmond.o'[email protected].

PMID: 21136903 PMCID: PMC4690473 DOI: 10.1002/prca.200780137

Abstract

The pathogenesis of progressive renal allograft injury, which is termed chronic allograft nephropathy (CAN), remains obscure and is currently defined by histology. Prospective protocol-biopsy trials have demonstrated that clinical and standard laboratory tests are insufficiently sensitive indicators of the development and progression of CAN. The study aim was to determine if CAN could be characterized by urinary proteomic data and identify the proteins associated with disease. The urinary proteome of 75 renal transplant recipients and 20 healthy volunteers was analyzed using surface enhanced laser desorption and ionization MS. Patients could be classified into subgroups with normal histology and Banff CAN grades 2-3 with a sensitivity of 86% and a specificity of 92% by applying the classification algorithm Adaboost to urinary proteomic data. Several urinary proteins associated with advanced CAN were identified including α1-microglobulin, β2-microglobulin, prealbumin, and endorepellin, the antiangiogenic C-terminal fragment of perlecan. Increased urinary endorepellin was confirmed by ELISA and increased tissue expression of the endorepellin/perlecan ratio by immunofluoresence analysis of renal biopsies. In conclusion, analysis of urinary proteomic data has further characterized the more severe CAN grades and identified urinary endorepellin, as a potential biomarker of advanced CAN.

Copyright © 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

References

  1. Transpl Int. 2002 Oct;15(9-10):494-501 - PubMed
  2. J Biol Chem. 2000 Dec 8;275(49):38176-81 - PubMed
  3. Ann N Y Acad Sci. 2004 May;1020:154-74 - PubMed
  4. J Am Soc Nephrol. 2004 Dec;15(12):3240-8 - PubMed
  5. Scand J Clin Lab Invest. 1994 May;54(3):199-206 - PubMed
  6. Am J Transplant. 2005 Apr;5(4 Pt 1):729-38 - PubMed
  7. Transplantation. 2004 Sep 15;78(5):719-24 - PubMed
  8. Transplant Proc. 2002 Feb;34(1):331-2 - PubMed
  9. Nephrol Dial Transplant. 2001 Dec;16(12):2401-6 - PubMed
  10. Clin Nephrol. 1991 Jun;35(6):255-62 - PubMed
  11. Proteomics. 2004 Apr;4(4):1159-74 - PubMed
  12. J Am Soc Nephrol. 2001 May;12(5):1026-1035 - PubMed
  13. J Am Soc Nephrol. 2004 Aug;15(8):2229-36 - PubMed
  14. Proteomics. 2005 Jun;5(9):2315-8 - PubMed
  15. N Engl J Med. 2000 Mar 2;342(9):605-12 - PubMed
  16. J Am Soc Nephrol. 2001 Mar;12(3):574-582 - PubMed
  17. Transplantation. 1999 Jan 15;67(1):103-9 - PubMed
  18. Clin Chem. 2002 Oct;48(10):1835-43 - PubMed
  19. Annu Rev Biochem. 1998;67:609-52 - PubMed
  20. Kidney Int. 2004 Jan;65(1):323-32 - PubMed
  21. Circ Res. 2004 Mar 5;94(4):550-8 - PubMed
  22. Kidney Int. 1999 Feb;55(2):713-23 - PubMed
  23. N Engl J Med. 2003 Dec 11;349(24):2326-33 - PubMed
  24. Transplant Proc. 2004 Jan-Feb;36(1):89-91 - PubMed
  25. Transplantation. 2004 Jul 27;78(2):269-75 - PubMed
  26. Transplantation. 1994 Dec 15;58(11):1195-8 - PubMed
  27. Ann Clin Biochem. 1993 Nov;30 ( Pt 6):550-4 - PubMed
  28. Proteomics. 2001 Jan;1(1):93-107 - PubMed
  29. Biochim Biophys Acta. 2000 Oct 18;1482(1-2):298-307 - PubMed
  30. J Clin Invest. 1985 Dec;76(6):2171-7 - PubMed
  31. Curr Opin Nephrol Hypertens. 2005 May;14(3):229-34 - PubMed
  32. Clin Chem. 2003 Oct;49(10):1615-23 - PubMed
  33. Kidney Int. 2002 Feb;61(2):727-33 - PubMed
  34. Kidney Int. 2000 Nov;58(5):2206-14 - PubMed
  35. Nat Genet. 1999 Nov;23(3):354-8 - PubMed
  36. J Biol Chem. 2003 Feb 7;278(6):4238-49 - PubMed
  37. Kidney Int. 2005 Jan;67(1):341-8 - PubMed
  38. Trends Cardiovasc Med. 2000 Feb;10(2):60-5 - PubMed
  39. Circ Res. 2002 Jul 26;91(2):158-64 - PubMed
  40. Transplantation. 1998 Jun 15;65(11):1506-9 - PubMed
  41. J Cell Biol. 2004 Jul 5;166(1):97-109 - PubMed
  42. J Biol Chem. 2005 Feb 25;280(8):7080-7 - PubMed
  43. Transplantation. 2001 Feb 27;71(4):515-23 - PubMed
  44. Eur J Clin Invest. 1993 Sep;23(9):572-9 - PubMed

Publication Types

Grant support